Algert Global LLC Increases Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Algert Global LLC boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 84.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,140 shares of the company’s stock after purchasing an additional 39,353 shares during the quarter. Algert Global LLC’s holdings in Hims & Hers Health were worth $2,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. boosted its stake in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $51.43 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $12.07 and a fifty-two week high of $72.98. The company has a market cap of $11.43 billion, a P/E ratio of 116.89 and a beta of 1.84. The firm has a 50-day simple moving average of $32.74 and a two-hundred day simple moving average of $32.16.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s quarterly revenue was up 110.7% compared to the same quarter last year. During the same period last year, the company earned $0.05 earnings per share. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. Morgan Stanley reduced their target price on Hims & Hers Health from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 29th. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. UBS Group reissued a “mixed” rating on shares of Hims & Hers Health in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Wednesday. Finally, Truist Financial cut their target price on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $37.67.

Insider Activity

In other news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. This represents a 56.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Chi sold 7,259 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $43.28, for a total transaction of $314,169.52. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at approximately $8,379,051.28. This represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 650,500 shares of company stock worth $25,790,311 over the last 90 days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.